Further investigation are needed to extend the number of clinical cases investigated, to analyze the co-localization of PTTG1 with MMP2, MMP9, VEGF and to clarify if a functional abrogation of PTTG1 might represent a novel therapeutic approaches in the clinical management of seminoma. This evidence concerns the gene MMP9 and seminoma.